No headlines found.
Adagio Medical Reports First Quarter 2025 Results
Business Wire (Thu, 15-May 4:05 PM ET)
Adagio Medical to Present at the BofA Securities 2025 Health Care Conference
Business Wire (Wed, 7-May 8:30 AM ET)
Business Wire (Thu, 17-Apr 8:30 AM ET)
Adagio Medical Appoints Deborah Kaster as Chief Business Officer
Business Wire (Mon, 31-Mar 4:01 PM ET)
Adagio Medical Reports Fourth Quarter and Full Year 2024 Results
Business Wire (Mon, 31-Mar 8:30 AM ET)
Adagio Medical Provides Clinical and Business Updates
Business Wire (Mon, 17-Mar 4:01 PM ET)
Business Wire (Fri, 28-Feb 8:30 AM ET)
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
Adagio Medical Holdings trades on the NASDAQ stock market under the symbol ADGM.
As of May 23, 2025, ADGM stock price climbed to $1.19 with 40,640 million shares trading.
ADGM has a beta of -0.78, meaning it tends to be less sensitive to market movements. ADGM has a correlation of 0.01 to the broad based SPY ETF.
ADGM has a market cap of $18.39 million. This is considered a Sub-Micro Cap stock.
ADGM support price is $1.04 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADGM shares will trade within this expected range on the day.